openPR Logo
Press release

NavigaWaldenstrom Macroglobulinemia Market Projected to Discern Stable Expansion During 2018 to 2026

01-15-2019 08:08 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Fact.MR

NavigaWaldenstrom Macroglobulinemia Market Projected

Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum, which leads to increased serum viscosity, and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to excess amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to symptoms. In the last few years, medical science has made much progress and a number of new treatments for this type of cancer have been introduced. However, very few studies have been done to compare the treatment options and thus, discover the best available option. Hence, there is no single treatment available that works for all patients. Symptomatic Waldenstrom macroglobulinemia patients are kept under observation and do not receive any treatment until symptoms show up.

Patients showing symptoms, such as anemia, hyperviscosity, cold-agglutinin disease, amyloidosis, peripheral neuropathy, etc., are considered for the treatment. Patients that show symptomatic hyperviscosity receive plasmapheresis along with rituximab treatment. In most cases of Waldenstrom macroglobulinemia, combination therapy with chemo and immunotherapy is recommended. Patients with this type of cancer may require stem cell transplantation during the latter stage. Hence, standard chemotherapy agents, such as chlorambucil, bendamustine, cladribine or fludarabine, etc., are not prescribed as first line therapy as they may affect the stem cells. 

Claim Sample Report For FREE: https://www.factmr.com/connectus/sample?flag=S&rep_id=2580 

Waldenstrom macroglobulinemia Market: Drivers and Restraints

Improving treatment options and diagnosis rate are the major factors expected to drive the growth of the Waldenstrom macroglobulinemia treatment market over the forecast period. Researchers have found that targeted therapy agents, such as Velcade and Kyprolis, show improved treatment outcomes. Increased treatment seeking rate is another important factor driving the growth of the global Waldenstrom macroglobulinemia treatment market. However, lack of a single standard treatment for all patients and disease complexity are the major factors limiting the growth of global Waldenstrom macroglobulinemia treatment market. High cost of therapy and side effects are some other factors that can hamper the treatment seeking rates and in turn, affect the global market growth. 

Waldenstrom macroglobulinemia Market: Segmentation

The global Waldenstrom macroglobulinemia market can be segmented on the basis of treatment, distribution channel and geography.

Based on treatment, the global Waldenstrom macroglobulinemia market is segmented as:

Chemotherapy
Alkylating agents
Cyclophosphamide (Cytoxan)
Bendamustine (Treanda)
Purine analogs
Fludarabine (Fludara)
Cladribine (2-CdA, Leustatin)
Corticosteroids
Prednisone
Dexamethasone (Decadron)
Others
Vincristine (Oncovin)
Doxorubicin (Adriamycin)
Targeted Therapy
Proteasome Inhibitors (bortezomib, carfilzomib)
mTOR inhibitors (Everolimus)
Bruton tyrosine kinase (BTK) inhibitors (ibrutinib)
Biological/immunotherapy
Monoclonal antibodies (rituximab, ofatumumab, alemtuzumab)
Immunomodulating Agents (Pomalidomide, Thalidomide)
Cytokines (Interfero)
Plasmapheresis
Stem Cell Transplantation
Based on distribution channel, the global Waldenstrom macroglobulinemia market is segmented as:

Hospitals
Specialty Cancer Clinics 
Waldenstrom macroglobulinemia Market: Overview

The global market for Waldenstrom macroglobulinemia is expected to witness moderate growth over the forecast period. The targeted therapy segment is expected to witness considerable growth during the forecast period due to increased adoption rate of Waldenstrom macroglobulinemia targeted therapy drugs. Hospitals are the preferred distribution channel for due to requirement of skilled professionals for planning of Waldenstrom macroglobulinemia treatment. Besides, other therapies, such as stem cell transplantation, require highly advanced medical infrastructure. Majority of these treatments are covered under medical part B and hence, hospitals are a preferred distribution channel for Waldenstrom macroglobulinemia treatments.

Request Full Report With TOC: https://www.factmr.com/connectus/sample?flag=T&rep_id=2580 

Waldenstrom macroglobulinemia Market: Regional Outlook

Geographically, the global Waldenstrom macroglobulinemia market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to be the dominant market in the global Waldenstrom macroglobulinemia market owing to high prevalence of the disease and better availability of medical resources in the region. The Waldenstrom macroglobulinemia market in Asia Pacific excluding Japan is expected to grow at a slow rate. Europe is expected to hold second largest share in the global Waldenstrom macroglobulinemia market throughout the forecast period. 

Waldenstrom macroglobulinemia Market: Key Players

Some of the players identified in the global include Baxter International Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Janssen Pharmaceutica NV (Johnson & Johnson), Merck & Co Inc., Hospira (Pfizer Inc.), Takeda Pharmaceutical Company Limited., Amgen Inc., Novartis AG and (Genentech) F. Hoffman-La Roche AG, among others. 

Grow Your Business From Expert Advice: https://www.factmr.com/report/2580/navigawaldenstrom-macroglobulinemia-market 

About US
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Rohit Bhisey
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release NavigaWaldenstrom Macroglobulinemia Market Projected to Discern Stable Expansion During 2018 to 2026 here

News-ID: 1497481 • Views: 210

More Releases from Fact.MR

Ready Meal Trays’ Myriad Applications and Recyclability Spearheading the Food …
The ready meal trays market continues to showcase stunning prospects, with overall incremental opportunity of over US$ 1.7 Billion by 2027 from 2019, according to a recent Fact.MR study. Growth in consumption of packaged food products across both developed as well as developing countries is anticipated to increase the demand for ready meal trays during the forecast period. Ready meal trays are increasingly used by food processors and fast service
Automation Making Significant Strides in the Container Handling Equipment Market …
According to a new Fact.MR study, the global market for container handling equipment is expected to increase at a value CAGR of 4.2% over the forecast period, to reach a market size of USD 2,316.6 Mn by 2029 from a calculated USD 1,541.2 Mn in 2019. The report provides potential takeaways that prove to be significantly useful for other market entrants in the container handling equipment market and evaluates trends
The Use of Automotive Actuators in Industrial Control Systems Will Bolster the A …
Fact.MR has recently published a report on the automotive actuators market. According to the report, in terms of revenue, the global automotive actuators market is estimated to expand at a CAGR of ~ 6.2% by value and ~ 5.2% by volume over the forecast period. Since the sales of automotive actuators is related to automotive production and vehicle parc, the increasing automotive production and vehicle parc across the globe is
Rising Inclination for Sustainable Packaging Solutions in F&B Sector Motivating …
Fact.MR has recently published a latest assessment report on Blow Molded Containers Market, which discourses prime facets associated to the global blow molded containers market. At present, the proliferation of sustainable food & beverage packaging applications at the global scale has been conveniently supporting sales of blow molded containers. Furthermore, the report predicts an average annual growth of roughly 5.7% in the global blow molded containers market during the stated

All 5 Releases


More Releases for Waldenstrom

Research Offers 08-Year Forecast on Waldenstrom Macroglobulinemia Market(Chemoth …
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum that causes increased serum viscosity and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to form large amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to the symptoms, although standard treatments are available. In the last few
04-22-2019 | Health & Medicine
Fact.MR
Waldenstrom Macroglobulinemia Market key Insights Based on Product Type, End-use …
Researchers have found that targeted therapy agents such as Velcade and Kyprolis are showing improved outcomes. Increased treatment-seeking rate is the other important factor projected to drive the growth of the global Waldenstrom Macroglobulinemia Market. However, lack of single standard treatment for all patients and disease complexity are the major factors expected to limit the growth of the global Waldenstrom macroglobulinemia market. High cost of therapy and side effects are
Waldenstrom Macroglobulinemia Market Challenges Analysis by 2026
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum that causes increased serum viscosity and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to form large amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to the symptoms, although standard treatments are available. In the last few
Navigawaldenstrom Macroglobulinemia By Key Players Overview (Baxter Internationa …
Waldenstrom macroglobulinemia Market: Overview Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum, which leads to increased serum viscosity, and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to excess amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to symptoms. In the last few years, medical science
Waldenstrom Macroglobulinemia Market | Key Players - Baxter International Inc., …
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum that causes increased serum viscosity and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to form large amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to the symptoms, although standard treatments are available. In the last few
Waldenstrom Macroglobulinemia Market Trends, Regulations And Competitive Landsca …
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum that causes increased serum viscosity and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to form large amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to the symptoms, although standard treatments are available. In the last few